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Chemotactic Factor Inactivator
in Sera of Sarcoid Patients
(May 1976)
Joan Kubik, B.A., American International College
Directed by:

Dr. Warren Litsky

ABSTRACT

Sera from eleven untreated patients diagnosed by x-ray
and biopsy as having sarcoidosis consistent with Stage II
of the disease

(hilar adenopathy with pulmonary infiltrates)

and thirteen appropriately diagnosed patients without
staging or regard to current therapy were found to contain
supernormal levels of chemotactic factor inactivator (CFI).
The serum inactivator irreversibly inhibited migration by
normal indicator polymorphonuclear leukocytes toward a
variety of chemotactic factors both complement independent
(bacterial factor) and complement dependent

(C^ and C^ frag¬

ments) in a chemotaxis assay system.
In the untreated Stage II group of sera, 8 of 11 showed

477o inhibition

t

12

(p 0.001).

In the mixed group, all 13

sera showed greater than 50% inhibition

t

10 (p 0.001).

Stage II sera exhibit selective inactivation of the

Vll

C3 fragment in comparison to normal controls.

Ultracentrifu¬

gal characterization by sucrose density gradient revealed a
biphasic inactivator pattern not distinguishable from that
of CFI found in normal human serum.

CFI activity was heat

labile in both sarcoid and normal sera.
chemotactic

factors directly.

CFI inactivated the

Tests for cell-mediated action

of the inactivator were inconclusive but indicate in some
cases cell mediation may occur either inhibiting or enhancing
cell migration.
Zymosan activation of most sarcoid sera showed normal
generation of complement-dependent chemotactic factors via
the alternate pathway.

This result indicated that sarcoid

sera are not deficient in the third through ninth component
of complement.
When miscellaneous normal and pathological sera were
tested for abnormal CFI

levels,

it was found that cirrhotics

and patients with Hodgkin's disease possessed elevated
levels of inactivator activity.
mixed results

in which the CFI

Cancer patients showed
levels did not coincide with

the severity of the patient's immediate condition.

These

patients were all undergoing therapy of various kinds.
Staging of a disease like sarcoidosis seems to be

Vlll

necessary if chemical indicators such as CFI are to be
assayed in order to assess disease process and progression
and attention must be paid to current therapy as CFI may
be very sensitive to various drugs.
CFI may turn out to be a general and very sensitive
indicator of pathological conditions occurring in the
body and its assessment in a wide variety of disease states
may be an important tool to aid in the diagnosis and
treatment of many human ailments.
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INTRODUCTION

The clinical manifestations of sarcoidosis were first
described a century ago by Hutchinson in 1875 (49).

Since

then, numerous investigators have made further contributions
to the description of the disease but, unfortunately, have
shed no more light on the cause, prevention or cure of the
disease.
Sarcoidosis occurs in many parts of the world with a
minimum occurrence of 5 per 100,000 in the general popula¬
tion (11) and may be hereditary to some degree as familial
occurrence is more frequent than could be expected from
statistical data (77).
The disease has been found in all age groups but occurs
most frequently between the ages of 20 and 40 years.

Both

sexes appear to be affected with equal frequency (19) and the
observed over-all mortality is about 6 per cent

(79) .

The modern concept of sarcoidosis is a multi-system
disorder in which:

1.) well-defined clinicoradiologic patterns

are associated with 2.) widespread granulomas and 3.)
depression of delayed-type hypersensitivity (53).

These

three common aspects have been used in the following
investigative approaches:

2

1.)

Diagnostically,

with sarcoidosis

the feature most often associated

is the bilateral hilar lymphadenopathy and

lung involvement with up to 97% of cases showing lung and
hilar node infiltration (20,

102).

This clinicoradiologic

pattern implicates an unknown airborn antigen which evades
removal by alveolar macrophages and succeeds in making con¬
tact with lymphoid tissue - presumably by way of the
lymphatics which drain to the hilar nodes.
lium,

In fact, beryl¬

a persistent and indestructible antigen,

this way to induce berylliosis,

acts

in just

a disease which presents a

clinical picture similar to sarcoidosis

(62).

Also, Refvem

demonstrated that quartz particles and other foreign bodies
may provoke

localized sarcoid formation and suggested that

calcareous spar found in certain soil types may be the
initiating agent
with sarcoidosis,

(73) .

Studies of World War II veterans

geographically represented according to

the birthplaces of the patients,

show the Northeastern and

Southeastern United States contain the highest concentration
of cases.

These areas are coincident with the pattern of

sandy soil according to Michael et al

(34,

67)

and with

forested or non-arid sections of the country according to
Cummings et al

(19).

In conjunction with forested areas,
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plant pathogens or products have been implicated with pine
pollen being mentioned frequently as a possible suspect (20).
2. )

Infectious agents can also produce granulomata

and a picture identical to sarcoidosis leading to incorrect
diagnoses.
rods,

Altered or anonymous mycobacteria, acid-fast

fungus, virus and mycoplasma

(14,

16,

52,

54, 74,

75,

89) among others have all been found in association with
sarcoidosis, but it remains unclear if the organisms preceed the disease or become established due to the patients'
altered immune response (2,

9).

Statistical interpretations

may prove to be of little value in attempting to pinpoint
the causative factor because sarcoidosis may be a symptom
complex rather than an entity.

If so, there could be

numerous etiological agents with no common element to a
large majority of cases
3. )

(16).

The depressed delayed-type hypersensitivity (DTH)

reaction characteristically observed in this disease is
expressed as a cutaneous anergy to a number of common
antigens.

This relative skin unresponsiveness has been

observed in as many as 75% of sarcoid patients using
tuberculin as the common antigen (35).

Sarcoid patients

also display decreased responsiveness to Candida albicans,
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histoplasmin, brucelline, coccoidine and mumps antigen
(32, 48, 51,
interest.

71).

This feature is of great immunologic

Normally the DTH response evolves slowly as a

consequence of a complicated interaction of cell types
and their products and is mediated by specifically reactive
thymus-derived lymphocytes

(T cells) rather than by con¬

ventional antibody molecules.

Because this normal sequence

of events does not occur in a majority of sarcoidosis
patients and in certain other diseases with widespread
involvement of the reticuloendothelial system (certain
neoplasms, Hodgkin's disease,
disseminated leishmaniasis)

lepromatous type of leprosy,

(26), these patients may be

productively studied to determine at what point the reaction
sequence breaks down and DTH fails to develop in comparison
to normally responsive control individuals.

The investi¬

gations can proceed at either cellular or chemical level.
The study of DTH,

itself, is extremely important as this

reaction seems to be responsible for a number of auto¬
immune diseases and allergies and underlies many other
immune reactions, including resistance to a variety of
infectious agents, rejection of allografts and resistance
to most tumors

(24).

5

This investigation of the immune surveillance system
is only one benefit;

the other applies directly to the

welfare of the patient himself.

The progressive disease course has only one treatment,
corticosteroid therapy, which is non-specific and not always
effective (80) resulting in the 670 mortality rate.

If,

in

fact, there is no single initiating agent or event responsible
for the disease, then research dealing with the expression
and consequences of the syndrome will be most important to
prevent permanent fibrosis and fatal sequaelae such as bulla
formation or cor pulmonale.
This investigation was directed toward the important
immunological event commonly observed in sarcoid patients the depressed delayed-type hypersensitivity (DTH) reaction
to a number of common antigens.
Development of the classic DTH reaction involves
migration of leukocytes

(mostly mononuclear)

location of the sensitizing antigen.

to the cutaneous

Both the polymorpho¬

nuclear and mononuclear leukocytes have demonstrated directed
migration along chemical gradients toward a variety of
complement-dependent and complement-independent chemotactic
factors.

These chemotactic

factors can be irreversibly

6

inactivated by a normal serum factor, chemotactic factor
inactivator (CFI).

Inactivation of the chemotactic factors

by CFI will block the directed leukocyte migration and
prevent leukocytic accumulation necessary to the expression
of the classic DTH reaction.

Recently, increased levels of

CFI have been found in the sera of patients with Hodgkin’s
disease (95).

Since both Hodgkin’s disease and sarcoidosis

display similar cutaneous anergy,

it was logical to assume

high levels of the inactivator in sarcoid sera as well.
The investigation of the relative amount of CFI

(6) in the

peripheral blood sera from patients with sarcoidosis was
conducted.

This area had not been previously investigated.

In fact, development of the chemotaxis assay for clinical
purposes has generated much interest but its use and
application have been hindered by lack of standardized
procedures and comparable data.
The determination of amounts of CFI in sera from
individuals with sarcoidosis relative to amounts normally
found in healthy control population could be of diagnostic
or prognostic value.

Further characterization of CFI,

itself, may lead to a more effective and specific treatment.

LITERATURE REVIEW

From an immunological viewpoint,

the depressed delayed-

type hypersensitivity (DTH) reaction expressed as cutaneous
anergy is the most interesting characteristic of sarcoidosis
Only a few other conditions present a similar finding and
these are diseases of a serious or fatal prognosis, such
as cancers of the reticuloendothelial system, Hodgkin’s
disease,

lepromatous leprosy,

and others

(29).

final stages of tuberculosis

The fact that sarcoidosis usually presents

a benign course offers great opportunity to investigate the
mechanisms of the altered DTH response without the com¬
plicating factors incurred in a fatally progressive disease.
The mechanism of DTH or cell-mediated immunity proceeds
in this manner:

Specific T or thymus-derived lymphocytes

are activated via antigenic stimulation leading to the
production of lymphokines.

The local release of these

pharmacologically active substances such as migration
inhibition factor (MIF), macrophage aggregation factor (MAF)
a chemotactic factor (CF) , a blastogenic

(BF) or mitogenic

factor (MF) , and a factor which stimulates the metabolic
activity of macrophages initiate an amplification step
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mainly involving non-specific recruitment of circulating
lymphocytes and monocytes.

The immigrant monocytes become

enlarged and altered in appearance due to an increase in
their content of lysosomes.

The protracted time course seen

in a DTH reaction may be caused by the time needed for
accumulation of sufficient monocytes and their subsequent
transfer to activated macrophages

(27,

62, 66, 87).

During peak intensity at 24 to 72 hours,

the cellular

composition of cutaneous DTH reactions shows lesions
populated exclusively by mononuclear cells which have been
demonstrated to be lymphocytes and macrophages

(23).

Although 757o of patients with sarcoidosis do not
respond to tuberculin antigen, passive transfer of tuberculin
hypersensitivity by means of leukocytes from sensitized
donors has been achieved,

showing that their skin is capable

of manifesting the DTH reaction (35,

86).

Both the induction and expression of DTH are a result
of the activation of specific thymus-derived lymphocytes

(22).

By use of various techniques to differentiate thymusderived (T)

lymphocytes from the bone marrow-derived (B)

lymphocytes

(7, 33,

55, 85), patients with sarcoidosis seem

to have a significantly lower proportion and total number of

9

circulating T cells in their peripheral blood (42).
there have been conflicting reports

However,

(63) and the determina¬

tion of absolute numbers and of proportions of peripheral
cells as a measure of immunologic responsiveness is,
in question (33,

itself,

68).

As very few specific T cells are needed for an in vivo
allergic response (25), appropriate subpopulations of T
cells may either be paralyzed by the unknown sarcoid antigen,
defective, or inactivated by a serum factor.

An absolute

lack of specific T cells does not seem likely as patients
are able to develop DTH reactions before the onset of the
disease and begin to return to reactivity after recovery
(17,

18, 37,

50).

There are a number of in vitro correlates to DTH by
which lymphocyte function can be assessed:
1.

Blast transformation of lymphocytes via antigen,
mitogens or mixed lymphocyte culture

2.

Lymphokine production as determined by:
A.

Effects on macrophages

B.

Cytotoxic effects on cultured cell lines

C.

Recruitment effect on non-sensitized
lymphocytes

(28)
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Blast

transformation of

in vitro lymphocyte cultures

has been assessed by determination of [j^hJ thymidine or l14c:
leucine uptake,
and impaired
In vitro

by morphologic

glucose metabolism
lymphocyte

correlates with the
parallels
response
(PHA),

to a

activation to tuberculin antigen

skin test

in sarcoidosis patients

largely normal,

cutaneous

anergy

indicate responses

or abnormally depressed
Dwyer,

Gee

transformation

56).

specific T cell mitogen,

been

play relative

by Mangi,

(8,

results with normal controls.

has

results

lymphoblastic

Also,

the

and

in vitro

phytohemagglutinin

although these patients
(35,

46,

64).

dis¬

Conflicting

can either be within normal range

(13,

58,

76,

and Kantor have

82).

Additional

studies

shown a marked disparity

between cutaneous

reactivity to Candida albicans,

which was

abnormal,

in vitro lymphocyte response

this

and

the

antigen which was
Normal

lymphocyte

corresponding
are not

normal

(64).

transformation in vitro with

in vivo anergy suggests

defective but could be coated

inhibitor

not

found

another T

that

the

lymphocytes

in vivo by a

serum

in a well-washed culture.

Depressed blastogenic
(Con A),

to

responses

cell mitogen

(41),

to Concanavalin A
and

impaired ability
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to develop cytotoxicity

in a mixed

also been reported

63).

(12,

Unfortunately,
are made difficult
of the disease
resulting
of

accurate
due to

lymphocyte culture have

interpretations

lack of staging

of many reports

(see Appendix A)

and non-comparability of assay systems

in conflicting reports

for virtually every area

investigation.
Correspondingly,

between cutaneous

some

investigators

anergy and

in vitro observations

clinical severity of the disease
Lymphocytes

transfer

factor

(4,

59,

60),

production of lymphokines
that

the

lymphocytes

is

in the DTH response.
sarcoidosis

show signs

by an increase

sarcoidosis

61), MAF

in vitro enforces
of normal

in their response
the other
Macrophages
of

KMIF

This

the concept
function,

to antigen

important

cell

but
(82).

involved

from patients with

pyroninophilia

monocytes by increased number of active
activity and

(101),

(36).

increased activation as

in cytoplasmic

higher phagocytic

(38),

patients have

and respond to MF

are capable

they may not be normal
The macrophage

(3,

or with

(56).

from hyporeactive

been shown to produce MIF

find no correlation

cells

(57),

determined
and the

displaying

increased IgG receptor
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activity (32) .

Macrophages from sarcoidosis patients

could be substituted interchangeably with normal macro¬
phages to enhance tuberculin induced lymphocyte trans¬
formation (47), however, normal sensitized control
macrophages could not reverse the unresponsiveness of
lymphocytes from patients with sarcoidosis in the presence
of tuberculin (36).
Consequently, the mass of evidence indicates that the
hyporeactivity of the sarcoidosis patient is not due to
the inability of his skin to express DTH response or of
lymphocyte and monocyte dysfunction.

This heightens the

possibility of serum factors which could be responsible
for the altered immunologic state seen in the disease.
Some investigators have reported various serum inhibitors:
Plasma from patients with sarcoidosis can significantly
decrease the response of normal lymphocytes to PHA, even
when added to optimal concentrations of pooled normal
plasma (64),
lation.

suggesting an inhibitor of lymphocyte stimu¬

Sera from sarcoidosis patients can also reduce

the transformation of normal lymphocytes in response to
Candida and mumps antigens.

This factor appears to be

heat stable at 56°C x 30 minutes

(5).
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Caspary and Field (15) have found lymphocytes from
sarcoidosis patients which are well sensitized to PPD^
in vitro while showing negative skin reactions.

They

also believe a serum factor may be responsible for this
interesting anomaly.
It has been shown that sensitized lymphocytes, when
stimulated by the sensitizing antigen, would produce a
soluble chemotactic factor which would attract large
numbers of mononuclear cells

(97).

Such a lymphokine

would explain the predominance of nonsensitive mononuclear
cells in the lesions of the delayed skin reaction.

The

chemotactic factor would attract circulating mononuclear
cells and the migration inhibition factor (MIF) would
keep them from migrating back out

(98).

A variety of chemotactic factors for neutrophilic
granulocytes is recognized; many of which are derived from
the complement system (91).

Chemotactic factors include:

^
Purified protein derivative or PPD is a somewhat
purified tuberculin product prepared by concentrating the
active proteins of autoclaved cultures of M. tuberculosis
by precipitation with ammonium sulfate.
A standard batch, PPD-S, has been designated as the
basis for the international unit:
1 tuberculin unit (TU)
equals 0.02 micrograms of total protein.

14

1.

Complement derived factors such as C3 fragment,
C5 fragment and activated C 567 complex

2.

Soluble bacterial factors

3.

Collagenolytic products

4.

Products of antigen stimulated lymphoid cells

5.

Lysosomal factors in neutrophils

(93,

94)

A variety of chemotactic factors for monocytes is
also recognized.
1.

These factors include:

The trypsin produced C5 fragment,

the same one

which has chemotactic activity for neutrophils,
and
2.

Lymphokine preparations from antigenically
stimulated sensitized lymphocytes

(95)

Because of this remarkable diversity of mediators,
inflammatory response must be kept in balance.

Naturally

occurring inhibitors destroy the kinins and the anaphylatoxins almost immediately upon generation in serum.

The

kinins and anaphylatoxins are inactivated by a serum carboxy%

peptidase B enzyme, anaphylatoxin inactivator (Al), which
removes the c terminal arginine residue in the peptides

(9).

A chemotactic factor inactivator (CFI) has also been
described in normal human serum;

the function of which is

15

to provide regulatory control over leukotactic mediators
generated in serum.

This inhibitor isolated from the

alpha and beta globulin regions of human serum appears to
act in an enzymatic-like fashion to inactivate complementderived and complement-independent chemotactic factors

(6) .

Imbalances in this naturally occurring CFI appear to
contribute to various disease courses

(43, 92, 99).

A deficiency of CFI has been shown in patients who
also have a deficiency of alpha-one anti-trypsin, a major
trypsin inhibitor.

A high percentage of these patients

develop pulmonary emphysema possibly the result of
uncontrolled reactions of trypsin-like enzymes.

With an

additional lack of chemotactic factor inactivator to
inactivate the larger than normal amounts of inflammatory
mediators which are being generated, a highly disadvan¬
tageous situation occurs resulting in inordinate delivery
of neutrophils and their enzymes to inflammatory
exudates

(100).

The opposite situation or increased levels of CFI
have been reported in the serum of patients with Hodgkin's
disease (95).

Patients with Hodgkin's disease fail to

express DTH reactions to a variety of antigens

(1) and

fail to mobilize inflammatory cells, both neutrophils and
mononuclear cells in dermal inflammatory sites

(72).

Increased levels of CFI could account for this inadequate
inflammatory cellular response.
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MATERIALS AND METHODS

Human Sera
Patient Sera:

Sera was obtained from two groups of

patients with radiologically and histologically
diagnosed sarcoidosis

(see Appendix B).

Group I consisted of eleven patients with sarcoidosis
diagnosed as Stage II

(79).

This consists of

bilateral hilar lymphadenopathy associated with
pulmonary infiltration, a progressive stage of the
disease with a 46% chance of resolution.

Patients

were untreated unless otherwise specified.
Group II consisted of a heterogeneous assortment of
13 appropriately diagnosed but unstaged sarcoidosis
patients without regard to therapy.
Normal Human Sera:

Control sera was obtained from

healthy individuals, many of whom were skin tested
to common antigens to insure normal cutaneous
reactivity.
Miscellaneous Sera:

Sera from normal pre-natal

patients, patients with cirrhotic liver disease,
cancer and trauma were used in comparison studies.

18

Chemotactic Assays:
Neutrophil chemotaxis was performed by the micropore
filter technique using modified Boyden's chemotactic
chamber (figures 1, 2,
method (figures 6,
in detail elsewhere

3, 4, 5) and Hill's improved assay

7, 8).

These techniques are described

(10, 44, 90).

Hill's method was also used without employing the
cytocentrifuge to directly sediment leukocytes on a
micropore filter.

Gravity sedimentation was used for this

micro method as was used with the modified Boyden's chamber
and found to be very satisfactory.
Indicator Cells:
Rabbit and human polymorphonuclear leukocytes were
used.
Assay Procedures:
Rabbit neutrophils were obtained from a glycogeninduced peritoneal exudate collected by a gravity tap In
heparinized (2-3 drops, 20,000 units per cc, Hiker I.abs,
Northridge, Ca.)

saline, centrifuged at 850-900 R.P.M.'s

and suspended in Hank's medium (Hank's Balanced Salt:
Solution, Grand Island Biological Company, Grand Island,

Figure 1.
Components of the modified Boyden's
chemotaxis chamber for use with rabbit indicator
cells.

Screw-in top

Rubber ring

Micropore
filter

Rubber ring

Cover glass

Body of
chamber

Injection
site
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Figure 2.
Chemotaxis chamber assembly for use
with rabbit indicator cells.

Figure 3•
Assembled chamber; LH - View of
bottom compartment for chemoattractant, RH View of upper compartment for indicator cells.

Figure 4.
View of lower compartment showing
injection site for the chemoattractant.

Figure 5.
Close-up view of injection site
showing passage of needle through the rubber
ring and into the chemoattractant compartment.
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Figure 6.
Components of the modified Boyden's
chemotaxis chamber for use with human indicator
cells.

Screw-in top which is the
upper compartment for
indicator cells

Micropore filter

Injection site
for the chemo¬
attractant
Plug

This arm-is
the lower com¬
partment which
holds the chemo¬
attractant

Body of chamber

Figure 7.
Assembled chemotaxis chamber, side
view.
This chamber used for assays using human
indicator cells.

Figure 8.
Assembled chemotaxis chamber, top
view.
Left hand well receives the chemoattractant;
right hand well receives the indicator cells.
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N.Y.) containing 0.05% bovine serum albumin at pH 7.4.
The upper compartment of each Boyden's chemotaxis chamber
contained a total of 2.5 x 10^ neutrophils in a total volume
of one milliliter.

The bottom compartment of each chamber

contained fluids to be tested for chemotactic activity
(see figures 1, 4, 5), usually 50 microliters chemoattractant
to 1 milliliter diluting fluid.
Hank's medium was used for dilution of both cells
and chemoattractants.

Filters of 0.65 micron pore size

(Millipore Corporation, Bedford, Mass.) were used and
chemotactic activity quantitated by counting the number
of cells which had migrated through channels of the filters
in ten high power fields under light microscopy (10 X
ocular, 45 X objective).
Human blood neutrophils were obtained by collecting 25
milliliters of blood in a sterile disposable plastic
syringe containing 20 units of heparin (20,000 units per
cc, Riker Labs, Northridge, Ca.) per milliliter of blood.
The syringe was placed in a vertical position and the
erythrocytes were allowed to settle over a 30 to 60 minute
period.

The leukocyte rich plasma was then expressed into
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sterile, disposable, plastic 12 x 75 millimeter test tubes
(Falcon Company, Oxnard, California).

A suspension of

polymorphonuclear leukocytes and Tissue Culture Medium 199
(Microbiological Associates, Inc., Bethesda, Maryland) was
prepared with a count of approximately 0.6 x 10^ cells per
milliliter;

0.1 milliliter of this suspension was diluted

to 0.4 milliliter with Medium 199 and deposited in the
top compartment of the chemotactic chamber.

The bottom

compartment holds the attractant also diluted in Medium 199
(see figure 6).

Filters of 5 micron pore size (Millipore

Corp., Bedford, Mass.) were used and chemotactic activity
quantitated by counting the number of cells that have
migrated completely through the filter within ten random
fields at high power (10 X ocular, 45 X objective) using
light microscopy.
After incubation of either type of chemotaxis chamber
for three hours at 37°C, the filters were removed and
dipped as rapidly as possible in absolute isopropyl alcohol
for fixation.

The filters were then taken through a

staining procedure:
1.

Hematoxylin (Harleco, Philadelphia, Pa.)
2 minutes

-
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2.

Water rinse

3.

Acid alcohol (3-4 drops HCL in 70% isopropyl
alcohol)

- 30 seconds

4.

Water rinse

5.

Bluing agent

(20 grams Mg SO^ - 7^0, and 2

grams NaHCO^ in one liter distilled t^O)

-

2 minutes
6.

Water rinse

7.

70% isopropyl alcohol - 30 seconds

8.

95% isopropyl alcohol - 30 seconds

9.

100% isopropyl alcohol - 30 seconds

10.

100% isopropyl alcohol - 1 minute

11.

100% xylene - 5 minutes

12.

100% xylene - 5 minutes

Then the filters were mounted on slides with Permount
(Fisher Scientific Co., Fairtown, New Jersey) lymphocyte
side down and polymorphonuclear leukocyte side up and
covered with a glass cover slip.

The attractant surface

of the filters was mounted upward so that the cells which
had migrated completely through the filter were visible in
the first plane of focus

(see figure 9).
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Figure 9.
Polymorphonuclear leukocyte
indicator cells which have migrated com¬
pletely through the micropore filter are
visible in the first plane of focus.
Hiffh power (X12 X45), light microscopy.
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Viability of cells as revealed by Trypan blue
exclusion (40) was 98% in all preparations.
blue test:

1 drop Trypan blue

The Trypan

(Direct Blue Biological

Stain, Matheson, Coleman & Bell Manufacturing Chemists,
Norwood, Ohio)
with

1

at 1 milligram/milliliter saline combined

drop of a cell preparation plus

logous serum.

drop of homo¬

1

After incubation for 15 minutes at 37°C,

cells were examined under light microscopy for evidence
of bluing which indicates cell death with concomitant
increase in permeability.
A nitro-Blue Tetrazolium (NBT)
Nitrophenyl-5,
diphenylene)

51 - diphenyl-3, 31-

(

[j.,

(3,

21 Di-P-

31-dimethoxy-4,

ditetrazolium

Grade III, Sigma Chemical Corp., St. Louis, Missouri)
assay was conducted on all normal and abnormal human cells
as an indicator of phagocytic activity (45, 81).

No

abnormal findings occurred in any cell preparation
indicating all subjects had polymorphonuclear leukocytes
qualitatively capable of normal phagocytosis and will not
be referred to again in this paper.

For each test 5 x 10

to 1 x 107 cells in Medium 199 was combined with 0.1
milliliter homologous serum, 2 milligram Zymosan A
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(Sigma Chemical Company, St. Louis, Missouri) and 0.1
milliliter NBT (2 milligram/milliliter).

Phagocytosis

was assayed as the reduction of the NBT dye which was
visualized as a definite blue color after incubation for
1 hour at 37°C.
Chemotactic Factors:
Preparation of chemotactic bacterial factor:

Bacterial

factor was obtained from 24 hour culture supernatants
Hank's medium)

(in

of Escherchia coli sterilized by filtration

through a 0.22 micropore filter and frozen in 3 milliliter
aliquots at -70°C.

Fifty microliter/milliliter of this

factor was used unless otherwise indicated.
Preparation of complement chemotactic factors:

Human

C3 and C5, purified according to the method of Nilsson and
Muller-Eberhard (69), were kindly supplied by Dr. P. A.
Ward, Farmington Health Center, Connecticut.

Chemotactic

fragments of C3 were produced by treatment with trypsin
(Mann Research Labs, Inc., New York) according to the
\

procedure of Bokisch & Muller-Eberhard (9).
In a similar manner chemotactic fragments of C5 were
prepared by trypsinization (96).

Purity and specificity of

the preparations were tested by Ouchterlony double
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diffusion - double dimension agar precipitation test

(see

Appendix C) using appropriate antisera which was also
supplied by Dr. Ward.

C3a an<^ ^5a activity was produced directly in normal
human serum by the method of Vallota and Muller-Eberhard
(88):

Epsilon-aminocaproic acid (EACA)

(IM)

(epsilon-

Amino-n-Caproic Acid, Sigma Chemical Co., St. Louis, Mo.)
was combined with normal human serum and incubated for 90
minutes yielding

EACA (0.5M) is combined with normal

human serum and treated with 20 milligram/milliliter of
boiled (30 minutes) baker's yeast at 37°C for 75 minutes
yielding

C$a.

Zymosan Activation of Serum Complement:
The alternate pathway for complement activation was
triggered in both normal and patient sera using Zymosan
as the initiating agent

(21).

To compare relative complement

levels in patients and controls, Zymosan A

(0.5 milligrams

per 50 milliliters serum) was incubated 30 minutes at 37°C
to activate the third through ninth components of complement
with the production of chemotactic activity.
Assay for Chemotactic Factor Inactivator

(CFI):

CFI levels were determined by combining 50 microliters
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test serum with 50 microliters of a chemotactic preparation
and incubating this mixture at 37°C for 30 minutes and then
60 minutes at 56°C.

Each sample was then diluted to 1

milliliter with either Hank's

(for rabbit cells) or Medium

199 (for human cells), depending upon the indicator cells
used in the assay system.

This was injected into the lower

compartment, or attractant side of the chamber (see figures
1,

6).

Irreversible inactivation of the chemotactic factor

by CFI was indicated by decreased migration of indicator
cells through the micropore filter in this test chamber as
compared to the migration seen in control chambers.

Control

chambers were loaded with 50 microliters of chemotactic
factor incubated with 50 microliters normal human serum at
37°C for 30 minutes and then inactivated at 56°C for 60
minutes.
Assay for Cell-Directed Mediators:
Bacterial factor (50 microliters) diluted to 1
milliliter with Medium 199 was placed in the lower chamber.
The upper chamber contained human polymorphs which had
been previously incubated with either 10% patient or 10%
normal control serum for 30 minutes at 37°C and then washed
with Medium 199.
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Assay for Relative Serum Complement Levels:
Rabbit neutrophils were used as the indicator cells
with Zymosan activated sera

(50 microliters) as the

attractant.
Ultracentrifugal Studies:
Ultracentrifugal characteristics of patient whole,
unconcentrated serum and a normal serum extract
with ammonium sulfate at 40% saturation,

(obtained

the soluble

fraction dialized against phosphate buffered (pH 7.3)
saline (PBS)^ and then concentrated to 1/3 the original
volume of serum) were determined by fractionation in a
sucrose density gradient

(7.5 - 35% sucrose in phosphate

buffer, pH 7.3, ionic strength 0.05) with centrifugation
at 55,000 R.P.M.'s for 16 hours at 40°C in an International
Hematocrit Centrifuge

(International Equipment Company,

Boston, Mass.) B-60 using a swinging bucket rotor.
Calculations:
In most cases, results were recorded as per cent
inhibition which was determined by calculating the ratio

Phosphate buffer saline is prepared by combining
160 grams NaCL, 27.6 grams NaH2 PO4-H2O, 16 milliliters
40% NaOH (6.4 grams) and distilled H2O up to a volume of
20 liters; pH to 7.4.
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of chemotactic activity in the presence of the inactivator
and in its absence, times 100 and then subtracting from
100;

or using this formula:

A

~
A

B

x

100

=

Per cent inhibition

where A is the sum of cells in 10 fields using normal
human serum as the source of CFI
where B is the sum of cells in 10 fields using patient
serum as the source of CFI
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RESULTS

Chemotactic Factor Inactivator in Normal Human Sera
Fourteen samples of fresh and frozen (-70°C) normal
human sera (NHS) were tested for CFI activity using
rabbit polymorphonuclear leukocytes in 0.057o bovine
serum albumin (BSA) as the indicator cells.

Prepared

bacterial factor (bf), C3 fragments and C5 fragments
were used as the attractants in modified Boyden's
chemotaxis chambers.
The data in Table I are representative of the general
findings concerning test values and ranges of CFI and
chemotactic responses in normal human sera.
Table I indicates degree of inactivation of chemo¬
tactic factors after incubation with NHS samples.

The

numbers represent the actual counts of indicator cells
which have migrated through the micropore filters in
response to chemotactic factors alone or after incubation
with the NHS samples.
the C3 and

Sample

#6

is the serum from which

fragments were obtained.

The lack of

migrational response of indicator cells indicates that
this serum was not originally chemotactic.

Similarly,
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Legend to Table I

*

The numbers

are direct counts

of indicator cells

which have migrated through the filter in ten random
fields
**

under high power,

Sample #6

is

fragments were

the

light microscopy.

serum from which

and

obtained.

Indicates serum inactivated by heating at

***

56°C for 60 minutes prior to incubation with the
chemotactic factors.
The

test counts

microliters
factors

represent cell migration to

50

of the complement-dependent chemotactic

and to

100 microliters bf incubated with

50 microliters NHS for 30 minutes at 37°C, followed
by assay set up.

Difference between test counts

and control counts minus background migration can
be used to
counts
were

calculate percent

from assays

inhibition.

Direct

in which the chemotactic

factors

incubated with serum show decreased migration.

Normal human sera
resulted

incubated with chemotactic

in an average

indicator cells.

20%

migration

factors

inhibition of
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use of serum alone as
the

sera

samples

As

indicated

chemotactic
resulted

are not

factor

indicates

that

in themselves chemotactic.

in Table I
(bacterial

in an average

indicator cells
factors

the chemoattractant

normal

serum incubated with

factor or

fragments)

20% migration inhibition of

compared to controls

incubated without

serum.

of chemotactic

Chemotactic C3

responded erratically often showing

fragments

increased migration of

indicator cells when incubated with normal human serum
(NHS).
Values

for

serum controls

test

sera are calculated against normal

in order to correct

of normal sera.

The

for

the

slight

inhibition

serum and negative control values

are

considered to be background migration and are routinely
subtracted
cent

from test counts prior to calculation of per

inhibition.
The

fresh sera tested were

found to react as

the

frozen specimens.

A number of combinations

the

and a number of pools of fresh serum

frozen samples

pooled among

reacted erratically and could not be used to prepare a
single

lot

of control

serum.

The reason for the erratic
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behavior

of pooled

specimens

perhaps being related
factor

ducibility.

All

were

in

treated

tested

to some unknown serum factors

incompatibility.

refrozen a minimum of

and

Sera could be

three

like manner

frozen,

times without

sera collected

immediately,

small vials

can only be conjectured,

-

for this

loss

thawed and
of repro¬

investigation

fresh blood sera were

the remainder being aliquoted

frozen at

or

into

-70°C with no serum aliquots

o

refrozen more

than three times.

yield cleaner results when the
patient,

were heat

60 minutes

Heat
CFI

factor

at

sera.

This

Bacterial

is

30 minute

However,

serum proteins

at

found to

either normal or
56°C

for

incubation with a

37°C.

the

to

testing effectively reduced

low levels

contained in normal

shown in Table II

factor was

for polymorphonuclear
60°C.

the

inactivation prior

activity even in

human

sera,

inactivated by heating at

following

chemotactic

The assay was

found

leukocytes

temperatures

coagulate

All tests using bacterial

and Figure

10.

to remain chemotactic
at

temperatures

higher than 56°C,

up

to

test

yielding unacceptable results.
factor as

the attractant and

Effect of heat on inactivator activity of normal human sera
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Per Cent Inhibition

REDUCTION OF SERUM INACTIVATOR ACTIVITY BY HEATING

Figure IQ.

Heat inactivation of serum

= 56°C X 60 min.)

prior to incubation with bacterial factor produced marked
reduction in serum inactivator activity indicating that CFI
is heat labile.
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all the serum controls were subjected to heat inactivation
prior to chemotaxis assay.
Using information such as found in Tables I and II,
a number of normal serum samples were selected according
to their similarity of response with bacterial factor in
the assay system.

These aliquots were utilized as control

sera in those tests not requiring autologous serum.

A

minimum of three different normal control sera was
included in each assay to insure a normal range value
with which to compare test sera values.

Chemotactic Factor Inactivator in Sera of Patients with
Sarcoidosis
The data in Tables III and IV indicate that
unfractionated, non-concentrated sera from patients with
sarcoidosis show significant inhibition of the chemotactic
activity.

In some sera,

greater than 80% of chemotactic

activity was destroyed although such high results were
not obtained within the Stage II group of patients' sera.
The Zymosan activation of sarcoid sera showed normal
generation of the complement-dependent chemotactic factors
(complement components three through nine) via the
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Table III.
Bacterial factor inactivator in Group I sarcoid sera
Serum tested
(coded)

B.T.
I.B.
E.B.
A •B •
G.C.
D.S.
J.D.
L.S.
C.D.
F.K.
R. C.

Inactivation of bf*
(per cent inhibition)

0
47
51
63
51
54
27
69
48
0
65

Chemotactic activity
generated in serum**
(per cent)

100
97
90
95
93
66
80
100
93

*

Assays were conducted by incubating 50 microliters
serum with 100 microliters bacterial factor.
Per cent
inhibition of normal control serum is taken to be
** Generation of chemotactic activity via the alternate
pathway was accomplished in the sarcoid sera by incubating
three milligrams zymosan to 0.1 milliliter serum at 37°C for
30 minutes and testing the serum so treated for chemotactic
activity.
Per cent activity in normal control sera is taken
to be 100^.
Group I (Stage II) sarcoid sera have elevated levels of
chemotactic factor inactivator.
These sera are generally
normal in their ability to generate chemotactic activity
following treatment with zymosan.
This generated activity
appears to be resistant to the effects of increased levels of
serum inactivators.
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Table IV.
Bacterial factor inactivator in Group II sarcoid sera
Serum tested
(coded)

#i
2
3
4
5
6
7
8
9
10
11
12
13

Inactivation of bf*
(per cent inhibition)

71
88
71
59
75

61

53
78
56
85
66
85
67

Chemotactic activity
generated in serum**
(per cent)

85
90
100
99
100
100
100

90
-

90
90
100

*

Assays were conducted by incubating 50 microliters
serum with 100 microliters bacterial factor.
Per cent
inhibition of normal control serum is taken to be 0^.
** Generation of chemotactic activity via the alternate
pathway was accomplished in the sarcoid sera by incubating
three milligrams zymosan to 0.1 milliliters serum at 37°C for
30 minutes and testing the serum so treated for chemotactic
activity.
Per cent activity in normal control sera is taken
to be 100^.
Group II (unstaged) sarcoid sera possess elevated levels
of chemotactic factor inactivator.
These sera show normal
chemotactic activity generation which seems resistant to the
effects of the increased levels of serum inactivators.

alternate pathway in these sera.

Response of normal serum

controls was assigned a value of 100% to which the sarcoid
sera were compared.

Chemotactic Factor Inactivator in Group I Sera
As determined by irreversible bacterial factor
inactivator, eight of eleven patients showed greater than
47% inhibition with a mean of 43%, and standard deviation of

t 12.

These results in Table III were obtained using 50

microliters of sera incubated with 50 microliters bacterial
factor at 37°C and inactivated for 60 minutes at 56°C.
This preparation was used as the attractant after dilution
to one milliliter^with either Hank's or Medium 199,
depending on indicator cells used.

Both rabbit and human

cell systems gave comparable results.

Chemotactic Factor Inactivator in Group II Sera
As shown in Table IV, all thirteen sera in this
heterogenous group showed greater than 50% inhibition with
the mean of 70% inhibition of chemotactic activity as com¬
pared to normal controls and standard deviation of ^ 10.

Specificity of the Chemotactic Factor Inactivator
The data presented in Table V and Table VI indicate
selective inactivation of the complement derived
ment in preference to the

fragment.

frag¬

Where performed,

this selective inactivation is significant in the Stage II
patients of Group I.
In Group II the results are variable with only five
of thirteen showing this selective inactivation.
of thirteen had no inhibition with either

Three

or

frag¬

ment preparation, two showed equal amounts of inactivation
and only one selectively inactivated the C5 fragment
preparation.

Although this group showed variability in

specificity, it uniformly exhibited inhibition when
bacterial factor was used as the attractant.

These finding

suggest that selection of patients with regard to staging
of the disease course would be of great importance if
comparable serological results are to be obtained.

Con¬

versely, the percent inhibition of the C3 fragment deter¬
minations may be an important indicator as to the
progression of the disease into Stage II.
In both groups of sera, the percent inhibition as
measured by inactivation of bacterial factor did not
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Table V.
Specificity of chemotactic factor inactivator in
Group I sarcoid sera

Serum tested
(coded)

B.T.
I.B.
E.B.
A.B.
G.C.
D.S.
J.D •
L.S.
C.D.

Inactivation of chemotactic factor*
(per cent inhibition)
C3 fragment
C5 fragment
Bacterial factor

52
03
42

02
02
10
12

28
38
10
36

02
01

46
14

03
0

09

0

47
51
63
51
54
27
69

48

*

Values represent per cent inhibition calculated on the
basis of activity of chemotactic factor incubated with patient
serum as compared to activity of the factor incubated with
normal control serum.
Per cent inhibition of normal control
serum is taken as 0fo.
Chemotactic factor inactivator in Group I (Stage II,
untreated) sarcoid sera shows selective inactivation of the
chemotactically active C3 fragment.
The chemotactic fragments of the third and fifth components
of human serum complement were produced by treatment of 56 micro¬
grams purified C3 and C5 with 5 micrograms trypsin in 50 micro¬
liters phosphate buffered saline, with incubation at 37°C for
five minutes.
Reactions were terminated by addition of 10 micro¬
grams soybean trypsin-inhibitor.
Fragments of C3 and C5 were
also produced by treatment with EACA as described elsewhere.
Fifty microliters of the C3 and C5 fragments were incubated
with 10 microliters serum.
One hundred microliters bacterial
factor was incubated with 50 microliters of serum.
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Table VI.
Specificity of chemotactic factor inactivator in
Group II sarcoid sera

Serum tested
(coded)

Inactivation of chemotactic factor*
(per cent inhibition)
C3 fragment
C5 fragment
Bacterial factor

3
4
5

46
65
25
30
14

6

49

0
0

7

-

-

#1
2

8
9

10
11
12

0
0
59

02
24

73
03
26

14

0
0
0
08
20

71
87
71
59
75
6l
53
78
56
85

66
85

*

Values represent per cent inhibition calculated on the
basis of activity of chemotactic factor incubated with patient
serum as compared to activity of the factor incubated with
normal control serum.
Per cent inhibition of normal control
serum is taken as 0^.
Chemotactic factor inactivator in Group II (unstaged,
treatment unknown) sarcoid sera shows selective inhibition of
the chemotactically active C3 fragment in only 5 of 11 samples.
Production of the chemotactic factors and quantities used
are as outlined in Table V.
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correspond with the degree of inhibition of the other
chemotactic factors.

For example,

in Group I, E.B.

had

51% inhibition of bacterial factor and 42%, inhibition
of the

fragment preparation while D.S. with 54%

bacterial factor inhibition only showed
inactivation.
in Figure

10%,

fragment

These data are graphically represented

11.

Zymosan Studies
In an attempt to demonstrate the ability of patho¬
logical sera containing high levels of CFI to be normal
in its generation of complement-dependent chemotactic
activity, Zymosan was used to activate the complement
sequence

in sera via the alternate pathway.

Tables III

and IV show that this Zymosan generated complementdependent chemotactic activity is normal.

These data

do not preclude the possibility that there may be an
earlier deficiency

(before C3)

in the complement sequence.

Heat Inactivation Studies
In order to determine the stability of the chemotactic
factor inactivator,

the sarcoid sera were incubated at

56°C for 60 minutes prior to the addition of the bacterial
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Figure XX.
Comparison of per cent inhibition of Group I (closed dot) and Group II (open
dot) sarcoid sera using three chemotactic factors as chemoattractants.
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factor.

The remaining steps of the assay were followed

as before except for the final 60 minutes of heat
inactivation at 56°C which was eliminated as it did not
alter the results.
The data in Table VII show that there is an average
of 22% increase activation in Group I

sera

Stage II) with prior heat inactivation.

(Sarcoidosis

Percent increase

activation was calculated by comparing indicator cell
migration from those tests using sera not heat inactivated
and those using the same sera subjected to heat inactivation
prior to'incubation with a chemotactic factor.

Group II

show more variability with an average of 122% increase
activation using twelve out of thirteen sera.

Cell-Directed Mediator
In order to determine if the serum inactivator works
directly on the indicator cells rather than on the chemo¬
tactic factor,

indicator cells of patients or normal

controls were incubated for 30 minutes at 37°C with 107.
homologous or 10% autologous serum.

These cells were

washed in Medium 199 and used in the assay system with
bacterial factor or Zymosan activated normal human serum
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Table VII.
Heat lability of serum chemotactic factor inactivator

Serum tested
(coded)

Group I

Group II

B.T.
E.B.
I .B.
A.B.
G.C.
D.S.
R.C.
J.D.
L.S.
#1

2
3
4
5

6

0
15
37

28
36
19

0
13
42
344
167

281
244

100

13

83
33
58
31
78
158
50
07

#1
#2
#3
#4
#5

0
0
0
0
0

7

8
9

10
11
12
Controls
NHS
NHS
NHS
NHS
Pool 1-4

Per cent increased migration
(enhancement) of indicator cells*

* Indicator cell migration toward 50 microliters serum
incubated with 100 microliters bacterial factor wasQcompared
to migration toward 50 microliters heated serum (56°C for 60
minutes) which was then incubated with 100 microliters
bacterial factor.
Per cent enhancement was calculated as
this ratio minus 1.00. For clarity, NHS controls were taken
as zero per cent enhancement.
The actual 17$ enhancement
(average value in a range from 0 to 32$) obtained from heat
inactivation of NHS has been subtracted from the values
given for sarcoid sera.
Substantial per cent enhancement of migration toward
bacterial factor incubated with the heated sera indicates
that serum chemotactic inactivator is heat labile at 56°C.
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as the attractant.
Eight patients were tested and a wide variety of
results occurred.
showed 36%,

Three of eight subjects had cells which

50% and 60%, inhibition when incubated with

autologous serum as compared to cells incubated with
homologous normal human serum.
no difference if patients'

Three of eight showed

cells were incubated with

either autologous patient serum or normal serum.

Two of

eight were enhanced in their migration through the filter
toward the chemotactic factor by their own serum and
actually inhibited by the normal serum.

One patient

showed enhancement by his own serum to bacterial factor
and similar percentage inhibition when Zymosan-activated
NHS was used as the chemoattractant.

These data are

represented in Table VIII.

Miscellaneous Studies
Table IX represents various data from non-pathological and pathological sera.

Cirrhotic Liver Diseases
Four patients with cirrhotic

liver disease were found

to have between 37% and 57% inhibition.

These results have
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Table VIII.
Effects of sarcoid sera on indicator cell migration

Sarcoid indicator
cells in 10%
autologous serum
(coded)
Cells B.T.

Chemotactic
factor

bf

NHS-Z*
I .B.

bf

NHS-Z
E.B.

bf

NHS-Z

Per cent
Inhibition

Per cent
Enhancement

50
50

0
0

36
32

0
0

0
50

42
0

G.C .

bf

0

0

A.B.

bf

0
0

0
0

NHS-Z

0
0

0
0

J.D.

bf

0

0

F.K.

bf

0

27

NHS-Z
D.S.

Normal human
indicator cells
in 10^ sarcoid
serum (coded)

bf

Chemotactic
factor

Per cent
Inhibition

Per cent
Enhancement

Serum G.C.

bf

0

43

A.B.

bf

0

0

D.S.

bf

NHS-Z

0
0

0
0

bf

0

27

F.K.

* NHS-Z was prepared by adding 0.5 milligrams zymosan
to 50 microliters normal human serum and incubated at 37°C
for 30 minutes.

Legend

to Table VIII

Indicator cells, whether sarcoid or normal, were
incubated with fresh autologous or fresh homologous
serum

(107.)

for 30 minutes at 37°C.

Where sarcoid cells were used,

the difference

between migration toward the chemoattractant of
cells incubated with autologous serum and cells
incubated with normal human serum were calculated.
Both per cent inhibition and per cent enhancement
were calculated by comparing the counts of cells
in 107, sarcoid serum to these cells in 10% normal
human serum.

Four out of eight patients appeared

to have no correctible serum defect which acted
directly on the cells.
Sarcoid serum produced no inhibition when incubated
with normal human indicator cells.
produced migration enhancement.
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-P
G
©
©

©

w

o

cd

co C
r—i CO

0)
o'h

©
u

CO

3
o
©

a) c

C O O H)

ovo vno

U -P

00 VAH CM
iP
xP

•P

©

©

55

£

to

-P
G
©
o

G
o
»P
-p
cd
P

O
-P
cd
o
*P

O O O UVt o
CM^t

oo

£
©
o

£h

P tuD'a a)
© *P £ p,

.H

Ph £ *P —"

©

o
CO

♦p
e

>s-P
-P G
©

>

o

rl

-p u
o 0)
Cd P.
g
o
•P
-p
cd

u
©

g
a)

lax)
>i
• -p
^ *P

o

•H c
-P
O
cd
-P

o
O

O UA O O O O
VPvOO o o o co

o
o

I

o
»P
-p
cd

o p
e ©

© g
x: ©
O

M >
©
«H
,a
©
Eh

•H
-p
O
©

O
•P
-P
o
©
■p
o
e
©
x:
o
70
G
©
>i

■p
•p

>

•P

-p
o
cd

■H
O
C
O
•p
-P
©
>
•P
-p
O
©
G
M

o
•p
-p
Pi *P
OP
-p *p
o xi
© G
CH *P
*H -p
© G
*P ©
o
©
-P u
o ©
© Ph
iP ^

£ 70
3 ©
U 70

vACMNOn

hP CAQO

vO-afr 0A0A

CM -j" 0A

O O 00 0-00 hP O 0-00

OOOOOOO
tP

\0 (A

VO

<; CQ O p

th cm o^-^- vnvo o-

tH CM OA

©
CO

Ph P< P< Ph Ph Pi

©
©
TO

©

©
©

OAC'A C'A CA C*A CA

©

©

>

£ ££

.P

©
•p
70

•P o o o o o o
-p o o o o o o

o

©

p
o

~c

u
*p

e e £

O On CM O CM O -3-

©
•p

Q

u
u
o

CM CM

c^oo o\o o co
On On 00 CO ON co

CO

•H
CO
o
c

CACM

*

© o
C/3 o

©

CM

•p

TO
o

>4-4 o vno hP

CM

ra o o

H O O
Cd Ph
-p
©
G
©

p
Ph

iP H CM tH 0A CM

©

e o oooo o

^ pq PO CO CQ cq CD
© :£ 5
3S 2S ^
p
Eh

fP
©

£
U
o
z

u

©
o
G
©
o

56

Legend to Table IX

*

Total white blood count and differential count

were performed by the hospital hemotology laboratory.
** Serum sample #7 was obtained from a patient in the
terminal stage of his disease.
Assays to determine inactivation of bacterial factor
by miscellaneous sera were conducted using 10 micro¬
liters serum to 200 microliters bacterial factor.

Per

cent inhibition was calculated using normal human serum
incubated with bacterial factor as a comparison value,
taken to be 0%>.
Chemotactic activity generation was determined using
0.5 milligram zymosan in 50 microliters serum and
incubated at 37°C for 30 minutes.

Per cent activity

in normal control sera is taken as

100%.

The determination of per cent increased migration was
performed by heating test sera for 60 minutes at 56°C
prior to incubation with bacterial factor.
' The per cent increase in migration is calculated as
the ratio of the test chemotactic value

(number of

cells migrating in ten random fields, high power light
microscopy)
serum, minus

to the control value using normal human
1.
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been corroborated by Dr.

E.

G. Maderazo of the Research

Department of the Hartford Hospital, Hartford, Connecticut
(personal communication).

Hodgkin's Disease
Three serum samples

(supplied by Dr.

University of Connecticut Health Center)

Peter A. Ward,
revealed

elevated levels of CFI and specificity for the C5 fragment.

Cancer
Sera from seven patients with cancer were tested for
CFI with special attention to cases in which the neoplasia
occurred in the lung.
therapy.

All of these patients were receiving

Results were variable as expected.

appeared to have normal CFI
between

68%,

levels.

and 20% inhibition.

Two of seven

The others showed

The ability of these

sera to generate complement-dependent activity is mixed.

Prenatal Normal
Two pools of twenty-four sera from healthy pre-natal
patients were tested,

yielding normal levels of CFI.

High White Count
Five sera from hospital patients with high white
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o

counts,
88%

14,200 - 21,400 cells per mmJ with greater than

polymorphonuclear leukocytes, were tested for CFI.

These patients were traumatized accident victims with no
known underlying pathological condition.

With one exception,

no abnormal levels of CFI were found in this group.

One

patient with a 30,000 white count did show significant
migration inhibition but no follow-up studies were possible
to rule out an unknown underlying disease condition.

Physical-Chemical Features of CFI in Sarcoidosis Sera
It has been shown that CFI in normal human serum can
be fractionated into two distinct components,
CFI activity,

for bacterial chemotactic factor

each with
(39).

Normal and sarcoidosis sera were separated by sucrose
density gradient.

The fractions were incubated with 50

microliters bacterial factor at 37°C for 30 minutes,

and

this mixture assayed for residual chemotactic activity.
Figure

12 shows the comparison of normal serum to

two test sera from patients who showed high levels of CFI.
One patient serum was selected from Group I and the other
from Group II.
In each of the three preparations,

a strikingly
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Per Cent Inhibition

SERUM INHIBITOR IN THREE PREPARATIONS

Figure 12.

Analysis by sucrose density gradient ultracentri¬

fugation of CFI in fractions of sarcoid sera and from an
extract of normal serum (obtained with ammonium sulfate at 40fo
saturation)*

Biphasic activity of CFI is similar in all

three preparations.
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similar pattern was observed: biphasic inactivator activity
appeared in the IgG marker position, with the second
position between albumin (BSA) and cytochrome markers.
These data indicate that CFI in sera from sarcoidosis
patients cannot be distinguished from CFI present in normal
human serum on the basis of ultra-centrifugal features.
Preliminary studies seem to point to selective inactivation
of complement-derived fragments by each peak.

One peak may

inactivate the C3 fragment and the other the C5 fragment.
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Discussion

Although a practical method was developed by Boyden
in 1962

(10)

to assay leukotaxis, this valuable tool has

not been utilized effectively in clinical situations.
The reasons are twofold:
1.

Studies of leukotaxis in research were done on

individual bases providing little standardization of
procedures with resultant difficulty in comparison of
data.
2.

Little progress has been made in the investigation

of the leukotactic responses which occur in various disease
states as compared to that found in a normal population.
Consequently this investigation had a dual approach.
First,

it outlined a simple, reproducible procedure

adaptable to a clinical laboratory situation.

No elaborate

apparatus was required and the 25 milliliters of whole
blood needed for testing leukocyte mobility and CFI activity
is a reasonable quantity easily obtainable on a routine in¬
patient basis.

Second,

leukotactic function was assayed

in a variety of pathological as well as normal conditions.
Rabbit leukocytes were demonstrated to function inter-

62

changeably with human leukocytes in their ability to
respond to measured levels of chemoattractants.

This sub¬

stitution of animal for human leukocytes as indicator cells
would be invaluable in the event that the required quantity
of whole blood could not be obtained.
The disease of major concern was sarcoidosis.

It was

found that the sera of these patients contained an
inactivator of a variety of experimentally produced chemo¬
attractants.

The chemotactic factor inactivator

(CFI) was

easily visualized in a leukotactic assay.
Two groups of patients with sarcoidosis were selected
for this study in an attempt to determine if staging of
the disease would be significantly reflected in the results.
Group I was composed of sera from Stage II individuals
representing an active state of the disease which had not
yet been treated,
of therapy.

especially with steroids,

the only method

Group II was composed of sera from randomly

chosen sarcoid patients, both unstaged and with unknown
status of current therapy.
The reasons for the choice of Group I
1.

include:

Possible influence by corticosteroids would be

eliminated and
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2.

Restriction to a designated stage of a sometimes

protracted illness would be useful for comparing test
results and could be indicative or predicative of disease
course.
Accordingly,

corticosteroids have been shown in

vitro to inhibit lymphocyte transformation
mitosis

(70) ,

and reduce response to PHA

(39) ,

inhibit

(63) but do not

affect the ability of monocytes and polymorphonuclear
leukocytes to either phagocytize or kill
vivo,

(30,

31).

In

steroids have been shown to produce a paradoxical

skin reaction in approximately one-third of all sarcoidosis
patients

(40,

87).

The inability of the skin of these

patients to respond to PPD and lymphokine
Concanavalin A stimulated lymphocytes)
by an injection of corticosteroid.

(from

can be reversed

Prednisone can cause

a previously non-responsive site to respond to a prior
PPD injection

(40).

This is exactly opposite to the

effect in normal persons and indicates that patients
with sarcoidosis have a block distal to lymphocyte
function correctable by steroids.

This paradoxical

response does not occur in other anergic states such as
cancer.
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Staging of the disease is also desirable as investi¬
gators who have compared the stages indicate Stage II
correlates with the anergic state in vivo,

reduced PHA

transformation, depressed cytotoxic capacity and significant
migration inhibition in vitro

(3,

12, 47).

Results of the grouping were not striking when
bacterial factor was used as the chemoattractant in the
chemotaxis assays

(Figure 11).

However,

the selective

inactivation of the C3 fragments was apparent in Group I,
indicating a real need to classify results of investiga¬
tions according to the stage of the disease in order to
get comparable data.

It seems especially important in a

disease such as sarcoidosis which can become chronic and
persist for years or which can spontaneously resolve
itself at any point along an active and sometimes fatally
(6%)

progressive disease course.
Throughout the study,

it became apparent that the

chemotaxis assay is very sensitive and responds to minute
amounts of reactants.

Bacterial factor can be made up in

large quantities and frozen in aliquots for long term
usage.
(60°C)

It is very stable at both low

(-70°C)

and high

temperatures and is homogeneous from aliquot to
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aliquot yielding highly reproducible results.
The complement derived fragments are prepared from
human sera and as such may bring interfering or enhancing
factors into the reaction.
It is

interesting to note,

coincidentally,

that persons

reaching Stage II have a 45% chance of resolution of the
disease,
group,

these data show an average 47% inhibition in this

and Becker et al reported 43% of sarcoid patients

(Stage II)

exhibit migration inhibition using the leukocyte

migration assay

(13).

As shown by the data,

there appears to be a defect in

the ability of sera from sarcoidosis patients to regulate
chemotactic mediators.
In each defective serum an excessive inactivation
of chemotactic activity is found.
of chemotactic factor inactivator
to inactivate

(CFI) possess the ability

leukotactic mediators that are both complement-

derived and complement-independent
inactivates

The supernormal levels

(Figure 11).

lymphocyte-derived chemotactic factors and

can inactivate chemotactic factors for monocytes,
as

CFI also

for neutrophils

(91,

97).

as well

This generalized action

along with elevated levels of CFI

found in sarcoid sera
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are consistent with the clinical observation of impaired
delayed-type hypersensitivity

(DTH)

responses in the

sarcoid patients.
Investigations of the histology of DTH reactions in
the skin have shown early

(2-3 hours) migration of

polymorphonuclear leukocytes especially around areas of
cellular damage along with mononuclear infiltration.
Mononuclear cells quickly dominate the picture,

possibly

due to the more rapid disintegration of the polymorphs
resulting in 86% lymphocytes and 14% macrophages in the
perivascular cell infiltrate at peak reaction
hours)

(48 -

96

(84).

A majority of cells which make up.the infiltrate
are not specifically sensitized cells
from the blood

(36).

(66)

and are derived

The mechanism for the accumulation

of these cells involves mediation by various chemotactic
factors

(83,

90,

91,

93,

94,

99).

Inactivation of these

factors by CFI must play a significant role in a variety
of pathological and non-pathological conditions.
levels

(low as

elevated as

Abnormal

in alpha-one anti-Trypsin deficiency and

in Hodgkin's disease) have already been shown

to coincide neatly with clinical findings and disease
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manifestations

(95,

100).

As in Hodgkin's disease,

sera

from sarcoid patients show elevated levels of CFI expressed
by increased inactivation of chemotactic factors.

These

two diseases are also similar in that they both express
cutaneous anergy.
Physical-chemical studies of sarcoid sera indicate a
bimodal activity of serum CFI.

In ultracentrifugal

preparations this biphasic activity is comparable to that
of CFI found in normal human serum (Figure 12)
be distinguished from it.
Dr.

Peter A. Ward

(6)

and cannot

This finding and others of

indicate that the heterogeneity of

this inactivator is due to two separate and distinct
substances.
This concept is reinforced by the data in Tables III
and IV and Figure 11 showing that the CFI in sera from
sarcoid patients of Group I

(Stage II)

selectively

inactivates the C3 chemotactic fragment.

Since CFI in

sera from Hodgkin's patients fails to inactivate the C3
fragment

(95) (contrasted with CFI isolated from normal

human serum),

the selective elevation of one of at least

two CFI moities

is a distinct possibility dependent on

the disease and its progress.
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Heat inactivation

(56°C for 60 minutes)

of sarcoid

sera results in significant enhancement of indicator cell
migration,
by heat

indicating that CFI activity can be destroyed

(Table II).

This suggests that CFI may have

enzymatic-like action.
Belcher, Carney and Nankervis described a heat stable
(56°C for 30 minutes)

factor in sarcoid serum which could

diminish the response of normal lymphocytes to phytohe¬
magglutinin

(5).

Mangi, Dwyer and Kantor observed the

same effect using sarcoid plasma even in combination with
optimal levels of normal human plasma

(64).

The stability

of these inhibitors separates them from CFI.
There is also some similarity between CFI and
anaphylatoxin inactivator
et al

(9).

(AI)

as described by Bokisch

AI has carboxypeptidase B activity and

largely accounts for the ability of normal human serum
to rapidly destroy the kinins generated by kallikrein
and the anaphylatoxin peptides C^a and C^a.
Treatment of purified C3 and C5 with trypsin leads
to the production of fragments with anaphylatoxin and
chemotactic activity.

Continued treatment abolishes the

anaphylatoxin activity whereas there is no demonstrable
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loss of chemotactic
of the
but

two

the

activity.

inactivators.

This

suggests non-identity

There are other differences,

final resolution of this question must await

availability of a highly purified preparation of CFI
Zymosan activation of most patient

the
(6).

sera showed

normal generation of complement dependent chemotactic
factors
This

via the alternate pathway

(Tables III

indicated that low total complement

levels

are probably not a complication of sarcoidosis
chemotactic

activity which is

is

I

and II

in normal human sera.
sufficient

to

there is

Perhaps

inactivate

the

these

(6).

a low level of CFI
low levels are not
of

factors which are

generated.

Deficiencies

prior to

would not be detected by

CFI

in serum

large quantities

complement-derived chemotactic

An attempt

and that

resistant to the

effects of inactivators naturally present
shown in Tables

in vivo

generated in human serum

by complement-activating substances

As

and IV).

in the complement cascade

to determine

this method.

the mode of action of the

either cell-directed or by directly inactivating the

chemotactic

factor,

was

mediation could not be

inconclusive.
shown with the

Cell directed
test method used.
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Unexpectedly,

some sarcoid sera produced actual enhance¬

ment of migration when incubated with the indicator cells
at a 10% concentration.

Similarly, unexplained enhance¬

ment was also noted using a leukocyte migration test in a
study of sarcoidosis, normal controls and a variety of
other disease states by Becker et al
of this

(3).

The results

investigation are so varied as to preclude any

attempt at interpretation.

However,

techniques for cell-

directed mediators seem to have some inherent problems.
A cell-directed mediator may be irreversibly bound to
cells and resist initial washing and,
refractile to correction.
is lightly bound,

Conversely,

thus, remain
if the mediator

it could be removed in the final wash

before assaying.
Berenberg et al incubated a concentrated CFI pre¬
paration in varying amounts with either the chemotactic
factors or the indicator cells.

As little as

10 micro¬

liters of the CFI preparation produced significant
migration inhibition when mixed with the chemotactic
factors, whereas at

least 50 microliters mixed with

indicator cells were needed to cause some decrease in
migration.

These results point to direct action on the
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factors and not on the cells

(6).

A number of miscellaneous sera were tested for CFI
activity using bacterial factor as the chemoattractant
with the expected results.
Sera from cirrhotic patients showed elevated levels
of CFI which could be heat inactivated.

Sera from

Hodgkin's patients also exhibited elevated levels of CFI.
Sera from cancer patients had mixed results.

Special

attention was given to sera from patients with neoplasia
of the lung which could be comparable to sarcoidosis
according to site.

Generally low levels of CFI were

found in these sera.
Pooled sera from normal prenatal patients and sera
from trauma victims with one exception gave normal results
as expected.

The one abnormal result in the group of

hospitalized accident victims might well have had an
underlying pathological condition unknown at the time of
admittance.
Sera from pregnant women were expected to show low
(normal)

levels of CFI because patients with sarcoidosis

who become pregnant experience a clearing of disease
manifestations with subsequent recurrence post partum.
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Increased production of adrenal steroids in the second and
third trimesters of pregnancy are thought to be responsible
for this phenomenon

(65,

78).

The chemotaxis assay can be used easily and effectively
to screen serum for chemotactic factor inactivator.

Sera

from healthy persons normally contain small amounts of the
inactivator.

Certain pathological conditions,

sarcoidosis, Hodgkin's disease,

such as

and cirrhosis are

associated with elevated serum levels of CFI.

Sera from

patients with sarcoidosis show an average 507. migration
inhibition in the assay using normal serum as a base-line
control.

Sera from patients with other diseases have

exhibited elevated ranges which indicate that the assay
could be used diagnostically.

Elevated levels of CFI

discovered in apparently healthy individuals by a
screening assay could indicate an incipient health
problem.

The standardized chemotaxis assay for CFI

would be a valuable laboratory aid especially as more
disease states are being investigated to determine
characteristic

levels of CFI.

APPENDIXES
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APPENDIX A

Staging of Sarcoidosis

Stage 0

-

chest x-ray normal

Stage I

-

hilar adenopathy with or without paratracheal
node involvement, but without infiltrative
disease

Stage II

-

hilar adenopathy and parenchymal lesions
with pulmonary infiltrates

Stage III

-

parenchymal lesions with pulmonary fibrosis
with or without hilar changes

Stage IV

-

x-ray findings of previous stages disappeared,
the x-ray now being normal

(Mangi, R.J. , Dwyer, J.M., Gee, B., & Kantor, F.S.:
Clin. exp. Immunology 18; 507, 1974, and Hedfors, E.,
Holm, G. , & Pettersson, D.:
Clin. exp. Immunology 17;
220, 1974.)
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APPENDIX B

Diagnostic Criteria
"The criteria for the diagnosis of sarcoidosis were
defined by a Subcommittee of the National Research Council
in October, 1956.
Sarcoidosis is a systemic disease, or group of
diseases, of undetermined etiology and pathogenesis.
Histologically, it is marked by the presence of epitheliodcell tubercles, showing little or no necrosis.
Varying
types of inclusions in giant cells may be present but are
not pathognomonic.
A similar histological picture may be
found in certain other diseases, especially in infectious
granulomas and in beryllium poisoning.
Clinically, the
disease most commonly involves lymph nodes, lungs, skin,
eyes, liver, spleen, and phalangeal bones.
The course
is usually chronic and constitutional symptoms vary
markedly.
More specific symptoms, when present relate
to tissues and organs involved.
The intracutaneous tuberculin test is frequently
negative, but a positive test does not controvert the
diagnosis.
Hyperglobulinemia and leucopenia are common
and hypercalcemia, hypercalciuria, elevated alkaline
phosphatase, and eosinophilia are variable but sometimes
significant features of sarcoidosis.
The diagnosis of sarcoidosis is based upon the above
clinical features associated with a compatible histological
picture, provided beryllium poisoning and known infectious
processes can be excluded.
Spontaneous clinical recovery, with or without
recognizable fibrosis, may result, or sarcoidosis may
persist for years with varying functional alteration of
the tissues or organs involved, or the disease may follow
a progressive course ending fatally."

(Ann.

Intern. Med.

Cummings Vol.

50,

1959,

pp 883-884)
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APPENDIX C

The Ouchterlony Test
Double Diffusion - Double Dimension
Specific antibodies and antigens which are introduced
into different regions of an agar gel diffuse freely toward
each other and form visible opaque bands of precipitate at
the junction of their diffusion fronts.
To perform the double diffusion - double dimension
test, a number of wells are cut into agar on a flat surface.
The wells are filled with appropriate solutions of antigens
and antiserum, covered to prevent evaporation and observed
periodically for several days.
When the antibodies meet
their corresponding antigen, a band of precipitation appears.
Purified preparations of C3 fragments were tested for
specificity using a C3 antiserum preparation.
A sharp
band of precipitation between the C3 well and the anti-C3
well indicated a relatively specific C3 preparation.
Anti-C^ was included as a control.

Well 1.

anti-C3»

well

2.

C3.

well

Sample Ouchterlony Test

3.

anti-C5
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